Long-term ocrelizumab in progressive multiple sclerosis

Affiliations

¹ Mellen Center for Multiple Sclerosis Treatment and Research, Department of Neurology, Neurological Institute, Cleveland Clinic, Cleveland, OH 44915, USA.
² Mellen Center for Multiple Sclerosis Treatment and Research, Department of Neurology, Neurological Institute, Cleveland Clinic, Cleveland, OH 44915, USA. Electronic address: cohenj@ccf.org.

Comment

Deja R Rose et al. Lancet Neurol. 2020 Dec.

. 2020 Dec;19(12):966-968.

doi: 10.1016/S1474-4422(20)30399-9. Epub 2020 Oct 29.

¹ Mellen Center for Multiple Sclerosis Treatment and Research, Department of Neurology, Neurological Institute, Cleveland Clinic, Cleveland, OH 44915, USA.
² Mellen Center for Multiple Sclerosis Treatment and Research, Department of Neurology, Neurological Institute, Cleveland Clinic, Cleveland, OH 44915, USA. Electronic address: cohenj@ccf.org.

No abstract available

Comment on

Long-term follow-up from the ORATORIO trial of ocrelizumab for primary progressive multiple sclerosis: a post-hoc analysis from the ongoing open-label extension of the randomised, placebo-controlled, phase 3 trial.
Wolinsky JS, Arnold DL, Brochet B, Hartung HP, Montalban X, Naismith RT, Manfrini M, Overell J, Koendgen H, Sauter A, Bennett I, Hubeaux S, Kappos L, Hauser SL. Wolinsky JS, et al. Lancet Neurol. 2020 Dec;19(12):998-1009. doi: 10.1016/S1474-4422(20)30342-2. Epub 2020 Oct 29. Lancet Neurol. 2020. PMID: 33129442 Clinical Trial.